4D Molecular Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of 4D Molecular Therapeutics generated cash of -$75,792,000, which is more than the previous year. Cash used in financing activities reached the amount of $156,832,000 last year. Net change in cash is therefore $196,757,000.
Cash Flow
| 2017 | 8.23M | 7.67M | 16K |
|---|---|---|---|
| 2018 | -16.25M | -414K | 84.57M |
| 2019 | -36.71M | -3.20M | -2.19M |
| 2020 | -50.90M | -1M | 278.98M |
| 2021 | -69.13M | -172.68M | 118.08M |
| 2022 | -86.68M | -17.05M | 3.08M |
| 2023 | -75.79M | 115.71M | 156.83M |
FDMT Cash Flow Statement (2017 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
Cash at beginning of period | 52.35M | 153.00M | 276.72M | 49.65M | 91.76M | 23.85M | 7.92M |
Operating activities | |||||||
Net income | -100.83M | -107.49M | -71.31M | -56.69M | -49.30M | -9.55M | -11.22M |
| Adjustments to reconcile net income to cash generated by operating activities: | |||||||
Depreciation and amortization | 5.74M | 3.88M | 3.02M | 1.44M | 1.00M | 697K | 626K |
Stock-based compensation expense | 19.66M | 17.12M | 13.79M | 4.98M | 3.54M | 0 | 256K |
| Deferred income tax benefit | 19.66M | 17.12M | 13.79M | 4.98M | 3.54M | 0 | 256K |
| Changes in operating assets and liabilities: | |||||||
Accounts receivable, net | 0 | 47K | 1.43M | -508K | 146K | -803K | -320K |
Inventories | 0 | 0 | -4.53M | -591K | 2.92M | 175K | -53K |
Accounts payable | 896K | -1.63M | 2.28M | 43K | 533K | 438K | -114K |
Cash generated by operating activities | -75.79M | -86.68M | -69.13M | -50.90M | -36.71M | -16.25M | 8.23M |
Investing activities | |||||||
Purchases Of Investments | -54.80M | -153.31M | -168.57M | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -2.77M | -11.53M | -9.11M | -1M | -3.20M | -414K | -573K |
Acquisitions Net | 0 | 11.53M | 9.11M | 0 | 0 | 0 | 24K |
Cash generated by investing activities | 115.71M | -17.05M | -172.68M | -1M | -3.20M | -414K | 7.67M |
Financing activities | |||||||
Common Stock Issued | 148.34M | 2.73M | 114.29M | 205.65M | 0 | 105K | 16K |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | -278.12M | -2.27M | 0 | 0 |
Repayments of term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash used in financing activities | 156.83M | 3.08M | 118.08M | 278.98M | -2.19M | 84.57M | 16K |
Net Change In Cash | 196.75M | -100.65M | -123.72M | 227.07M | -42.10M | 67.91M | 15.92M |
Cash at end of period | 249.10M | 52.35M | 153.00M | 276.72M | 49.65M | 91.76M | 23.85M |
| Data source | Data source | Data source | Data source |